Tag: topical formulation

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra^® for men - in a proprietary topical formulation demonstrated to work where women need it most

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius...

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

CRANFORD, N.J. , July 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received...

Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsTopical formulation

Mouser Electronics Receives NXP’s Top Customer Count Asia 2025 Award For the First Time

The OREO Brand & BTS Movement is On! Introducing the Limited Edition OREO & BTS Cookies

Solidion Technology Announces $35 Million Private Placement of Common Stock Priced Above Market Under Nasdaq Rules

Tag: topical formulation

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us